{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T04:46:50Z","timestamp":1785818810078,"version":"3.56.0"},"reference-count":14,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Nephrol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate whether immunoglobulin replacement therapy (IgR), initiated for infection prophylaxis in patients with ANCA-associated vasculitis (AAV) receiving rituximab, is associated with changes in infection burden, disease activity, and the ability to de-escalate immunosuppression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed a retrospective single-center study of 16 patients with AAV treated with rituximab who developed secondary hypogammaglobulinemia (IgG &amp;lt;600 mg\/dL) and subsequently received IgR between 2014 and 2024. Patients receiving IgR for primary immunodeficiency were excluded. Data collected included demographics, ANCA serotype, relapse history, infection burden, immunosuppressive regimen, and serum IgG levels before and after IgR. Primary outcomes were infections and disease relapse before versus after IgR initiation. Secondary outcomes included changes in serum IgG and rituximab use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Prior to IgR, mean IgG was 287 \u00b1 98 mg\/dL, 14\/14 patients tested had impaired vaccine responses, and 13\/16 (81%) experienced recurrent or severe infections. Seven patients (44%) had at least one disease relapse while on rituximab maintenance. After IgR, mean IgG increased to 1018 \u00b1 234 mg\/dL, with normalization in 14\/15 (93%). Recurrent or severe infections decreased to 1\/16 (6%). Following IgR initiation, no disease relapses were observed during a median follow-up of 29.0 months (IQR 14.5-61.4; range 2.8-127.8), despite rituximab discontinuation in 10 patients and dose-interval extension in the remaining 6 patients. IgR was discontinued in 3 patients without relapse.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this cohort of AAV patients with rituximab-associated hypogammaglobulinemia, IgR demonstrated improved immunoglobulin levels and reduced infection burden and was associated with sustained disease remission despite immunosuppression de-escalation. Further studies are needed to determine whether IgR influences disease activity in AAV.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fneph.2026.1861999","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T04:27:37Z","timestamp":1785817657000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Immunoglobulin replacement therapy in antineutrophil cytoplasmic antibody-associated vasculitis with rituximab-associated hypogammaglobulinemia: infection outcomes and disease course in a retrospective cohort"],"prefix":"10.3389","volume":"6","author":[{"given":"Matthew","family":"Gross","sequence":"first","affiliation":[{"name":"Johns Hopkins Medicine, Johns Hopkins University","place":["Baltimore, MD, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditi","family":"Singh","sequence":"additional","affiliation":[{"name":"Johns Hopkins Medicine, Johns Hopkins University","place":["Baltimore, MD, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raj","family":"Roshan","sequence":"additional","affiliation":[{"name":"Johns Hopkins Medicine, Johns Hopkins University","place":["Baltimore, MD, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Azar","sequence":"additional","affiliation":[{"name":"Johns Hopkins Medicine, Johns Hopkins University","place":["Baltimore, MD, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duvuru","family":"Geetha","sequence":"additional","affiliation":[{"name":"Johns Hopkins Medicine, Johns Hopkins University","place":["Baltimore, MD, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2021.05.021","article-title":"KDIGO 2021 clinical practice guideline for the management of glomerular diseases","volume":"100","year":"2021","journal-title":"Kidney Int"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa127","article-title":"Serious infectious events and immunoglobulin replacement therapy in patients with autoimmune disease receiving rituximab: A retrospective cohort study","volume":"72","author":"Stabler","year":"2021","journal-title":"Clin Infect Dis"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.671503","article-title":"Rituximab associated hypogammaglobulinemia in autoimmune disease","volume":"12","author":"Tieu","year":"2021","journal-title":"Front Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223559","article-title":"Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: An international randomised controlled trial","volume":"82","author":"Smith","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keac716","article-title":"Predictors of hypogammaglobulinemia in ANCA-associated vasculitis after a rituximab-based induction: A multicentre study","volume":"62","author":"Podest\u00e0","year":"2023","journal-title":"Rheumatol (Oxford)"},{"key":"B6","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1136\/ard-2022-223764","article-title":"EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update","volume":"83","author":"Hellmich","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez311","article-title":"The therapeutic efficacy of intravenous immunoglobulin in anti-neutrophilic cytoplasmic antibody-associated vasculitis: A meta-analysis","volume":"59","author":"Shimizu","year":"2020","journal-title":"Rheumatol (Oxford)"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/93.7.433","article-title":"Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity","volume":"93","author":"Jayne","year":"2000","journal-title":"QJM"},{"key":"B9","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.ejim.2023.06.021","article-title":"Intravenous immunoglobulin therapy in antineutrophil cytoplasmic antibody-associated vasculitis","volume":"117","author":"Benavides-Villanueva","year":"2023","journal-title":"Eur J Intern Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.70310","article-title":"Evidence- and consensus-based recommendations for the screening, diagnosis, and management of secondary hypogammaglobulinemia in patients with systemic autoimmune rheumatic diseases by the Taiwan College of Rheumatology experts","volume":"28","author":"Tsao","year":"2025","journal-title":"Int J Rheum Dis"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2011.01.002","article-title":"Preparations of intravenous immunoglobulins diminish the number and proinflammatory response of CD14+CD16++ monocytes in common variable immunodeficiency (CVID) patients","volume":"139","author":"Siedlar","year":"2011","journal-title":"Clin Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1126\/science.291.5503.484","article-title":"Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor","volume":"291","author":"Samuelsson","year":"2001","journal-title":"Science"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.2009.01217.x","article-title":"In vitro comparison of the complement-scavenging capacity of different intravenous immunoglobulin preparations","volume":"97","author":"Spycher","year":"2009","journal-title":"Vox Sang"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/art.39472","article-title":"Intravenous immunoglobulin as an immunomodulating agent in antineutrophil cytoplasmic antibody-associated vasculitides: A French nationwide study of ninety-two patients","volume":"68","author":"Crickx","year":"2016","journal-title":"Arthritis Rheumatol"}],"container-title":["Frontiers in Nephrology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneph.2026.1861999\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T04:27:37Z","timestamp":1785817657000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneph.2026.1861999\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,4]]},"references-count":14,"alternative-id":["10.3389\/fneph.2026.1861999"],"URL":"https:\/\/doi.org\/10.3389\/fneph.2026.1861999","relation":{},"ISSN":["2813-0626"],"issn-type":[{"value":"2813-0626","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,4]]},"article-number":"1861999"}}